The Biggest Story in Metabolic Research Right Now
GLP-1 receptor agonists have gone from a niche area of incretin biology to arguably the most consequential drug target discovery of the last half-century. What started as “gut hormones that help regulate insulin” has exploded into a research landscape spanning metabolic disease, cardiovascular biology, appetite regulation, neurodegeneration, and addiction. And the compounds keep getting more sophisticated — from single-receptor agonists to dual and triple-receptor molecules that simultaneously target GLP-1, GIP, and glucagon receptors.
Here’s the science behind the family, and why each generation represents a fundamentally different pharmacological strategy.
These compounds are supplied exclusively for in vitro and preclinical research. They are not intended for human consumption, therapeutic application, or diagnostic use.
GLP-1: The Hormone That Started Everything
GLP-1 (glucagon-like peptide-1) is produced by L-cells in the small intestine in response to food intake. Its natural job is metabolic coordination after eating:
- Insulin secretion: GLP-1 stimulates glucose-dependent insulin release from pancreatic β-cells — the “dependent” part is key, because the insulin response is proportional to blood glucose. This is what makes GLP-1 biology inherently safer than exogenous insulin.
- Glucagon suppression: Reduces glucagon secretion from α-cells, decreasing hepatic glucose output.
- Gastric emptying: Slows stomach emptying, producing a feeling of fullness and smoothing post-meal glucose spikes.
- Appetite: GLP-1 receptors in the hypothalamus and brainstem mediate satiety signaling — the “full” signal that reduces food intake.
The problem with native GLP-1: it gets destroyed within 2-3 minutes by DPP-4 (dipeptidyl peptidase-4). It’s a brilliant signaling molecule with a terrible half-life. The entire field of GLP-1 agonist research has been about engineering analogs that retain the biology while surviving long enough to be useful.
Single-Receptor Agonists: GLP-1R Only
GLP-1S (Acylated GLP-1 Analog)
GLP-1S represents the acylation strategy for half-life extension. A fatty acid chain is attached to the peptide, which allows it to bind reversibly to serum albumin. This albumin binding protects against DPP-4 degradation and slows renal clearance, extending the half-life from minutes to approximately one week.
Key modifications beyond acylation include amino acid substitutions that further resist DPP-4 cleavage. The result: once-weekly dosing in research protocols, with sustained GLP-1R activation throughout the dosing interval.
The research on GLP-1S has expanded far beyond glucose metabolism. Published studies have explored cardiovascular effects (reduced major adverse cardiac events), renal protection, liver fat reduction, and neurological applications.
Dual-Receptor Agonists: GLP-1R + GIPR
GLP-1T (Dual GIP/GLP-1 Agonist)
GLP-1T took the field in a new direction by combining GLP-1 receptor agonism with GIP (glucose-dependent insulinotropic polypeptide) receptor agonism in a single molecule. Why add GIP? Two reasons:
- Complementary metabolic effects: GIP and GLP-1 activate distinct but overlapping signaling pathways in β-cells, potentially producing additive insulin secretion and β-cell protection.
- Different CNS appetite circuits: GIP receptors in the brain contribute to appetite regulation through pathways that only partially overlap with GLP-1-mediated satiety. Dual targeting may engage a broader spectrum of appetite-control circuitry.
The research comparing single vs. dual receptor agonism has shown that GLP-1T produces greater metabolic effects than GLP-1R agonism alone in multiple preclinical models — more weight reduction, better glucose control, and potentially different body composition effects.
Triple-Receptor Agonists: GLP-1R + GIPR + GCGR
GLP-3R (Triple Agonist)
GLP-3R is the latest evolution: a single molecule that activates GLP-1, GIP, and glucagon receptors simultaneously. Adding glucagon seems counterintuitive — glucagon raises blood sugar. But glucagon also:
- Increases energy expenditure — thermogenesis and metabolic rate
- Drives hepatic lipid oxidation — fat burning in the liver
- Reduces food intake — through CNS mechanisms partially distinct from GLP-1
The glucose-raising effect of glucagon agonism is counterbalanced by the glucose-lowering effects of concurrent GLP-1 and GIP agonism. The net result, in preclinical research: greater weight loss than dual agonism, with glucose control maintained through the compensatory incretin effects.
The Engineering Behind These Molecules
All three generations share common design strategies:
- DPP-4 resistance: Amino acid substitutions at the N-terminus prevent enzymatic cleavage
- Acylation: Fatty acid chains enable albumin binding for extended half-life
- Receptor selectivity tuning: Specific amino acid choices determine relative potency at each receptor subtype
- C-terminal modifications: Amidation and other modifications improve stability
The progression from single → dual → triple agonism reflects a deepening understanding of metabolic physiology: these receptor systems didn’t evolve in isolation, and targeting them in combination may better recapitulate the complex signaling that coordinates metabolic health.
Product Specifications
- GLP-1S — Single GLP-1R agonist, acylated, weekly dosing
- GLP-1T — Dual GLP-1R/GIPR agonist, acylated, weekly dosing
- GLP-3R — Triple GLP-1R/GIPR/GCGR agonist
All independently verified at Janoshik Analytical.
Key References
- Drucker DJ. GLP-1 receptor agonists: mechanisms of action. J Clin Invest. 2007;117(1):24-32.
- Frias JP, et al. Dual GIP/GLP-1 receptor agonism in metabolic research. N Engl J Med. 2021.
- Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist. Cell Metab. 2022.
Browse the full Metabolic Research category or explore our complete catalog.